Centratherin Exhibits Antitumor Activity Against Glioblastoma Cells

Area of Science:

• Neuro-oncology
• Natural Product Chemistry
• Molecular Biology

Background:

• Glioblastoma (GB) is an aggressive brain tumor with poor prognosis despite standard temozolomide (TMZ) therapy.
• Novel therapeutic strategies are urgently needed to overcome GB's resistance to apoptosis and its invasive nature.

Purpose of the Study:

• To investigate the antitumor potential of centratherin, a sesquiterpene lactone, against glioblastoma.
• To evaluate centratherin's effects on glioblastoma cell viability, proliferation, migration, invasion, and cell death mechanisms.

Main Methods:

• Testing centratherin on established and patient-derived glioblastoma cell lines and healthy astrocytes.
• Assessing cell viability, proliferation, migration, invasion, cytoskeletal organization, DNA damage, and cell death pathways (necrosis, necroptosis).

Main Results:

• Centratherin demonstrated dose-dependent cytotoxicity against glioblastoma cells, sparing healthy astrocytes.
• It inhibited glioblastoma cell proliferation, migration, and invasion, and disrupted cytoskeletal organization.
• Centratherin induced double-strand DNA breaks and cell death primarily via necrosis, independent of necroptosis, and did not sensitize cells to TMZ.

Conclusions:

• Centratherin exhibits selective cytotoxic effects against glioblastoma, targeting key malignant phenotypes.
• Its ability to induce necrosis and disrupt cellular functions makes it a promising candidate for glioblastoma treatment.
• Further research into centratherin's distinct mechanisms may offer advantages over current glioblastoma therapies.